[Advances of pathological diagnosis and molecular pathology of lung neuroendocrine neoplasms].
Zhonghua Bing Li Xue Za Zhi
; 53(2): 109-115, 2024 Feb 08.
Article
in Zh
| MEDLINE
| ID: mdl-38281776
ABSTRACT
The pathological classification and diagnostic criteria for lung neuroendocrine neoplasms (NENs) in the 2021 World Health Organization (WHO) lung tumor classification are similar to the prior classifications. However, the advances on the molecular studies of lung NENs have shown that both small cell lung carcinoma and large cell neuroendocrine carcinoma are highly heterogeneous tumors with neuroendocrine characteristics and can be subclassified based on the features of genomics or transcriptomics, which are valuable in the diagnosis of lung NENs subtypes and patient treatment. In addition, it is necessary to interpret emerging concepts such as "lung neuroendocrine tumor G3" and "histological transformation" from pathological perspectives, as well as to know the novel neuroendocrine biomarkers such as INSM1 and POU2F3. This article summarized the diagnostic changes and the advances of molecular pathology of lung NENs based on the latest WHO classification and molecular research.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pancreatic Neoplasms
/
Neuroendocrine Tumors
/
Carcinoma, Neuroendocrine
/
Lung Neoplasms
Type of study:
Diagnostic_studies
Limits:
Humans
Language:
Zh
Journal:
Zhonghua Bing Li Xue Za Zhi
Year:
2024
Document type:
Article
Affiliation country:
China
Country of publication:
China